Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Hold rating on Integra Lifesciences (NASDAQ:IART) but lowers the price target from $32 to $26.
July 30, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities has maintained a Hold rating on Integra Lifesciences but has lowered the price target from $32 to $26.
The lowered price target from $32 to $26 by Truist Securities suggests a less optimistic outlook for Integra Lifesciences, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100